服用三苯氧胺或芳香化酶抑制剂的患者注意事项。

Mary Heery
{"title":"服用三苯氧胺或芳香化酶抑制剂的患者注意事项。","authors":"Mary Heery","doi":"10.6004/jadpro.2023.14.6.2","DOIUrl":null,"url":null,"abstract":"Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamoxifen therapy improves survival and reduces the risk of developing recurrent invasive breast cancer by up to 40%. Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Research on aromatase inhibitors has demonstrated improved survival in postmenopausal women, postmenopausal women with metastasis, and premenopausal women under the age of 35 with ovarian ablation. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence and improve the effectiveness of these medications. Advanced practitioners are in a position to prescribe these therapies, review medication interactions, educate patients, impact patients’ quality of life, improve patients’ sense of control, and increase patients’ partnerships with their oncology providers.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"14 6","pages":"478-482"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/ef/jadpro-14-478.PMC10558019.pdf","citationCount":"0","resultStr":"{\"title\":\"Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors.\",\"authors\":\"Mary Heery\",\"doi\":\"10.6004/jadpro.2023.14.6.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamoxifen therapy improves survival and reduces the risk of developing recurrent invasive breast cancer by up to 40%. Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Research on aromatase inhibitors has demonstrated improved survival in postmenopausal women, postmenopausal women with metastasis, and premenopausal women under the age of 35 with ovarian ablation. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence and improve the effectiveness of these medications. Advanced practitioners are in a position to prescribe these therapies, review medication interactions, educate patients, impact patients’ quality of life, improve patients’ sense of control, and increase patients’ partnerships with their oncology providers.\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"14 6\",\"pages\":\"478-482\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/ef/jadpro-14-478.PMC10558019.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.6.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.6.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors.
Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamoxifen therapy improves survival and reduces the risk of developing recurrent invasive breast cancer by up to 40%. Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Research on aromatase inhibitors has demonstrated improved survival in postmenopausal women, postmenopausal women with metastasis, and premenopausal women under the age of 35 with ovarian ablation. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence and improve the effectiveness of these medications. Advanced practitioners are in a position to prescribe these therapies, review medication interactions, educate patients, impact patients’ quality of life, improve patients’ sense of control, and increase patients’ partnerships with their oncology providers.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Carcinoid Heart Disease. How Do We Achieve Value-Based, Patient-Centered Care? Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube. Sutimlimab for Cold Agglutinin Disease. Artificial Intelligence: How Is it Relevant to Advanced Practitioners?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1